(0.13%) 5 187.70 points
(0.08%) 38 884 points
(-0.10%) 16 333 points
(-0.18%) $78.24
(0.36%) $2.22
(-0.11%) $2 321.70
(-0.16%) $27.50
(0.19%) $990.30
(0.09%) $0.930
(0.26%) $10.93
(0.10%) $0.800
(0.01%) $91.45
Live Chart Being Loaded With Signals
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide...
Stats | |
---|---|
本日の出来高 | 835 088 |
平均出来高 | 1.35M |
時価総額 | 68.54B |
EPS | $0 ( 2024-05-02 ) |
次の収益日 | ( $3.40 ) 2024-08-01 |
Last Dividend | $0.950 ( 2024-03-07 ) |
Next Dividend | $0 ( N/A ) |
P/E | 50.89 |
ATR14 | $0.122 (0.05%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-05-03 | Byington Carrie L | Buy | 129 | Rights to Common Stock Under BD Deferred Compensation Plan |
2024-05-03 | Jones Christopher Ian Montague | Buy | 129 | Rights to Common Stock Under BD Deferred Compensation Plan |
2024-04-30 | Garrison Michael David | Sell | 1 715 | Common Stock |
2024-04-04 | Neal Shana Carol | Sell | 1 921 | Common Stock |
2024-03-14 | Spoerel Thomas J | Sell | 282 | Common Stock |
INSIDER POWER |
---|
68.42 |
Last 100 transactions |
Buy: 255 893 | Sell: 56 118 |
ボリューム 相関
Becton Dickinson and Co 相関
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Becton Dickinson and Co 相関 - 通貨/商品
Becton Dickinson and Co 財務諸表
Annual | 2023 |
収益: | $19.37B |
総利益: | $8.17B (42.17 %) |
EPS: | $4.97 |
FY | 2023 |
収益: | $19.37B |
総利益: | $8.17B (42.17 %) |
EPS: | $4.97 |
FY | 2022 |
収益: | $18.87B |
総利益: | $8.48B (44.92 %) |
EPS: | $5.93 |
FY | 2021 |
収益: | $20.25B |
総利益: | $9.43B (46.56 %) |
EPS: | $6.92 |
Financial Reports:
No articles found.
Becton Dickinson and Co Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0.870 (N/A) |
$0.910 (N/A) |
$0.910 (N/A) |
$0.910 (N/A) |
$0.910 (N/A) |
$0.950 (N/A) |
$0.950 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | $0.0213 | 1973-02-28 |
Last Dividend | $0.950 | 2024-03-07 |
Next Dividend | $0 | N/A |
Payout Date | 2024-03-29 | |
Next Payout Date | N/A | |
# dividends | 165 | -- |
Total Paid Out | $47.51 | -- |
Avg. Dividend % Per Year | 1.05% | -- |
Score | 4.85 | -- |
Div. Sustainability Score | 8.57 | |
Div.Growth Potential Score | 4.28 | |
Div. Directional Score | 6.43 | -- |
Year | Amount | Yield |
---|---|---|
1973 | $0.0213 | 0.94% |
1974 | $0 | 0.00% |
1975 | $0 | 0.00% |
1976 | $0 | 0.00% |
1977 | $0 | 0.00% |
1978 | $0 | 0.00% |
1979 | $0 | 0.00% |
1980 | $0 | 0.00% |
1981 | $0 | 0.00% |
1982 | $0 | 0.00% |
1983 | $0.0525 | 2.00% |
1984 | $0.0716 | 3.11% |
1985 | $0.0750 | 3.10% |
1986 | $0.0829 | 2.18% |
1987 | $0.0940 | 1.52% |
1988 | $0.109 | 1.74% |
1989 | $0.124 | 1.99% |
1990 | $0.134 | 1.76% |
1991 | $0.143 | 1.57% |
1992 | $0.150 | 1.85% |
1993 | $0.166 | 1.75% |
1994 | $0.187 | 2.13% |
1995 | $0.210 | 1.78% |
1996 | $0.232 | 1.25% |
1997 | $0.229 | 1.08% |
1998 | $0.295 | 1.21% |
1999 | $0.339 | 0.81% |
2000 | $0.365 | 1.43% |
2001 | $0.374 | 1.12% |
2002 | $0.384 | 1.18% |
2003 | $0.439 | 1.43% |
2004 | $0.614 | 1.53% |
2005 | $0.738 | 1.35% |
2006 | $0.869 | 1.47% |
2007 | $0.995 | 1.45% |
2008 | $1.156 | 1.37% |
2009 | $1.327 | 1.95% |
2010 | $1.493 | 1.95% |
2011 | $1.669 | 2.02% |
2012 | $1.800 | 2.48% |
2013 | $1.981 | 2.56% |
2014 | $2.18 | 2.05% |
2015 | $2.40 | 1.76% |
2016 | $2.64 | 1.83% |
2017 | $2.87 | 1.78% |
2018 | $2.95 | 1.39% |
2019 | $3.02 | 1.41% |
2020 | $3.12 | 1.17% |
2021 | $3.28 | 1.34% |
2022 | $3.50 | 1.42% |
2023 | $3.68 | 1.44% |
2024 | $0.950 | 0.39% |
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
LOMA | Dividend Knight | 2023-06-30 | Quarterly | 2 | 5.23% | 8.53 |
JQC | Dividend Royal | 2023-11-14 | Monthly | 22 | 6.56% | 8.50 |
NCV | Dividend Royal | 2024-02-09 | Monthly | 22 | 7.68% | 8.50 |
SBR | Dividend Royal | 2023-11-14 | Monthly | 38 | 7.74% | 8.50 |
SCM | Dividend King | 2023-12-15 | Monthly | 13 | 7.08% | 8.50 |
MTR | Dividend Diamond | 2023-10-30 | Monthly | 39 | 10.10% | 8.50 |
PDI | Dividend Royal | 2023-11-10 | Monthly | 13 | 7.86% | 8.50 |
SJT | Dividend Royal | 2023-11-29 | Monthly | 39 | 12.52% | 8.50 |
ORC | Dividend Royal | 2023-11-29 | Monthly | 12 | 9.23% | 8.50 |
SRV | Dividend Royal | 2023-12-04 | Monthly | 18 | 7.53% | 8.50 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.0676 | 1.500 | 8.65 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0246 | 1.200 | 9.18 | 10.00 | [0 - 0.3] |
returnOnEquityTTM | 0.0519 | 1.500 | -0.534 | -0.801 | [0.1 - 1] |
payoutRatioTTM | 0.826 | -1.000 | 1.740 | -1.740 | [0 - 1] |
currentRatioTTM | 1.411 | 0.800 | 7.94 | 6.36 | [1 - 3] |
quickRatioTTM | 0.789 | 0.800 | -0.0655 | -0.0524 | [0.8 - 2.5] |
cashRatioTTM | 0.327 | 1.500 | 9.30 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.333 | -1.500 | 4.46 | -6.69 | [0 - 0.6] |
interestCoverageTTM | -724.00 | 1.000 | -10.00 | -10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | 12.99 | 2.00 | 5.67 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 10.45 | 2.00 | 4.77 | 9.55 | [0 - 20] |
debtEquityRatioTTM | 0.702 | -1.500 | 7.19 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.412 | 1.000 | 6.46 | 6.46 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.110 | 1.000 | 9.80 | 9.80 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.209 | 1.000 | 9.95 | 9.95 | [0.2 - 2] |
assetTurnoverTTM | 0.364 | 0.800 | -0.906 | -0.725 | [0.5 - 2] |
Total Score | 8.57 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 51.38 | 1.000 | 4.91 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0519 | 2.50 | -0.343 | -0.801 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 10.45 | 2.00 | 6.52 | 9.55 | [0 - 30] |
dividendYielPercentageTTM | 1.572 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 12.99 | 2.00 | 5.67 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.826 | 1.500 | 1.740 | -1.740 | [0 - 1] |
pegRatioTTM | 0.339 | 1.500 | -1.074 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.191 | 1.000 | 7.73 | 0 | [0.1 - 0.5] |
Total Score | 4.28 |
Becton Dickinson and Co
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is based in Franklin Lakes, New Jersey.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。